



**AUSTRALIA BIOTECH  
INVEST & PARTNERING 2018**  
Connecting capital with innovation

Tuesday 30 October  
Sofitel Melbourne on Collins  
[ausbiotechinvestment.com.au](http://ausbiotechinvestment.com.au)

#AusBioInv



### Company profile

Imagion Biosystems, has developed a new medical imaging technology which can detect specific cancers non-invasively. The proprietary technology uses magnetic nanoparticles with tumour-targeting antibodies to “tag” specific cancers. Only those particles that are attached to the tumour are measured by the sensors, while unattached nanoparticles are not detected greatly improving sensitivity. Unlike scans, this detection technology doesn’t expose the patient to ionising radiation or radioactive tracers, and uses magnetic fields orders of magnitude less than used in MRI. Preclinical evidence supports the technology is more sensitive than current imaging technologies, thus facilitating earlier detection, and will differentiate malignant from benign tumours.

### Speaker Profile



#### **Robert Proulx, President & Chief Executive Officer**

Robert Proulx has over 25 years’ experience bringing life science and medical device products through development and commercialization.

As President at Imagion Biosystems, he led the effort to restructure the company and list on the Australian Securities Exchange. Previous employment experience includes President and General Manager for Silicon Biosystems developing an imaged based “liquid biopsy” diagnostic platform for circulating tumor cells. His career in marketing and sales management spans the computer, life science and medical diagnostics industries. He is currently also serves as an independent director for Quantapore, a private company developing a nanopore-based next generation sequencing platform.

Robert holds a Master of Arts and Bachelor of Arts from The State University of New York at Albany and an Executive Master of Business Administration from the Penn State Smeal College of Business.